Chronic myelogenous leukemia (CML) is also known as chronic granulocytic leukemia or chronic myeloid leukemia. CML is an overgrowth of granulocytes, a type of white blood cell; its cause is unknown. The disease accounts for about 20 percent of adult leukemias in Western countries. This year, approximately 5,050 individuals will be diagnosed with CML, and an estimated 470 will die from the disease. In most cases, CML is characterized by a chromosomal abnormality that is known as the Philadelphia chromosome. Treatment usually consists of various chemotherapeutic agents used to disrupt the production of leukemic cells. These treatments may be followed by stem cell transplant.
- $22.05 million in FY02-06
- Research Progam Fact Sheet
- 61 awards in FY02-06
- Previous Proposals Recommended for Funding